Five-Year Survival and Veiligheid of SABR in Patients with Unresectable Locally Gevorderd Non-Small Cell Longkanker unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-gerandomiseerde Fase 2-Trial

In the early analysis of START-NEW-ERA phase 2 trial, SABR had optimal local control and promising overall survival without ≥G3 toxicity in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) unfit for concurrent chemoradiation therapy (ChT-RT). We report the 5-year outcomes with a focus on patterns of local recurrence (LR).